Arcellx Inc (ACLX.O) has experienced a significant decline of 4.51% in its stock price, hitting a 20-day low. This movement reflects the company's recent struggles in the market.
The broader market is currently trading sideways, with major benchmarks showing mixed signals and a lack of clear direction. Despite the overall market being up by approximately 0.60%, Arcellx's performance stands out negatively.
Investors are closely monitoring the stock as it approaches critical support levels. The technical indicators suggest that further declines could be possible if the stock fails to recover from this low.
Market analysts suggest that the lack of relevant news may indicate that technical factors are primarily driving the stock's movement, rather than any specific company-related news.
Wall Street analysts forecast ACLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACLX is 113.14 USD with a low forecast of 100.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast ACLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACLX is 113.14 USD with a low forecast of 100.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 68.260
Low
100.00
Averages
113.14
High
130.00
Current: 68.260
Low
100.00
Averages
113.14
High
130.00
UBS
Buy
initiated
$100
2026-01-07
Reason
UBS
Price Target
$100
AI Analysis
2026-01-07
initiated
Buy
Reason
UBS assumed coverage of Arcellx (ACLX) with a Buy rating and $100 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.
Wells Fargo
initiated
$100
2025-12-22
Reason
Wells Fargo
Price Target
$100
2025-12-22
initiated
Reason
Wells Fargo initiated coverage of Arcellx with an Overweight rating and $100 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ACLX
Unlock Now
Wells Fargo
initiated
$100
2025-12-22
Reason
Wells Fargo
Price Target
$100
2025-12-22
initiated
Reason
Wells Fargo initiated coverage of Arcellx with an Overweight rating and $100 price target. The firm views the company's anito-cel as a "future pillar" in the treatment of multiple myeloma. Anito-cel can expand and capture a majority of the BCMA CAR-T market in fourth-line multiple myeloma given its "attractive" efficacy and safety profile, the analyst tells investors in a research note. Wells expects "rapid uptake" upon launch in 2026. The firm also sees opportunities for Arcellx in CAR-T despite recent data from competitors.
Citi
Buy
maintain
$110
2025-11-24
Reason
Citi
Price Target
$110
2025-11-24
maintain
Buy
Reason
Citi believes today's weakness in Arcellx is "an overreaction to the highly preliminary" Phase 1 inMMyCAR data for Kelonia Therapeutics' KLN-1010. While the achievement of MRD-negativity is a positive early signal, the study featured just three patients and a maximum of three months' follow-up, "leaving critical questions about response durability entirely unanswered," according to the firm, which would be buyers on the weakness. Citi maintains a Buy rating and $110 price target on Arcellx shares.
About ACLX
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
